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Ginseng saponins exert various important pharmacological effects with regard to the control of many
diseases, including cancer. In this study, the anticancer effect of ginsenosides on human cancer cells was
investigated and compared. Among the tested compounds, ginsenoside-Rh2 displays the highest
inhibitory effect on cell viability in HepG2 cells. Ginsenoside-Rh2, a ginseng saponin isolated from the
root of Panax ginseng, has been suggested to have potential as an anticancer agent, but the underlying
mechanisms remain elusive. In the present study, we have shown that cancer cells have differential
sensitivity to ginsenoside-Rh2-induced apoptosis, raising questions regarding the speciﬁc mechanisms
responsible for the discrepant sensitivity to ginsenoside-Rh2. In this study, we demonstrate that AMP-
activated protein kinase (AMPK) is a survival factor under ginsenoside-Rh2 treatment in cancer cells.
Cancer cells with acute responsiveness of AMPK display a relative resistance to ginsenoside-Rh2, but
cotreatment with AMPK inhibitor resulted in a marked increase of ginsenoside-Rh2-induced apoptosis.
We also observed that p38 MAPK (mitogen-activated protein kinase) acts as another survival factor
under ginsenoside-Rh2 treatment, but there was no signaling crosstalk between AMPK and p38 MAPK,
suggesting that combination with inhibitor of AMPK or p38 MAPK can augment the anticancer potential
of ginsenoside Rh2.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Ginseng saponins have various pharmacological effects with re-
gard to the modulation of the progression of many diseases,
including cancer, diabetes, immune disorders, and neurodegenera-
tive disease [1]. Ginseng might mediate its antidiabetic action
through a variety of mechanisms, including modulation of insulin
secretion [2], regulation of apigenic transcription factor PPAR-g [3],
and control of glucose level [4] and glucose transport [5]. There have
also beenmany reports describing the immunomodulating effects of
ginseng. Ginseng extracts modulate cytokine production [6],
enhance CD4(þ) T cell activities [7], and restore T lymphocytes
function [8]. In addition, ginseng saponins have anticarcinogenic
effects through diverse mechanisms, including cell cytotoxicity
[9,10], antitumor promotion related to antimetastasis [11] and the
inhibition of angiogenesis, synergistic effects in combination withry and Molecular Biology, Medical
inseng, Published by Elsevier. Opechemical therapeutic agents [12], and reducing multidrug resistance
[13]. Although many ginsenosides have been reported to show
anticarcinogenic effects, there is no report focusing on the compar-
ison of the cytotoxic effects of ginsenosides in various cancer cells.
The major active components of ginseng are ginseng saponins,
ginsenosides. Recently, ginsenoside-Rh2 (Fig. 1), a plant glycoside
with a dammarane skeleton, has been shown to induce apoptosis in
a caspase 3,8-dependent manner [14] or the activation of cyclin
A-Cdk2 by caspase 3-mediated cleavage of p21(WAF1/CIP1) [15].
Also, ginsenoside-Rh2 was shown to inhibit proliferation by
inducing the protein expression of p21 and reducing the protein
levels of cyclin D, which resulted in the downregulation of cyclin/
Cdk complex kinase activity, a reduction in phosphorylation of pRb,
and the inhibition of E2F release [16] or modulation of MAP kinases
[17] in various cancer cells; however, their mechanisms have not
yet been clearly elucidated.Research Center and Biomedical Science Institute, School of Medicine, Kyung Hee
n access under CC BY-NC-ND license. 
Fig. 1. Chemical structure of ginsenoside-Rh2.
M.-J. Kim et al / AMPK in G-Rh2-induced apoptosis 17AMP-activated protein kinase (AMPK) is a heterotrimeric serine/
threonine kinase that consists of a catalytic a subunit and regula-
tory b and g subunits, each of which has at least two isoforms. The
activation of AMPK occurs by binding of AMP to the g subunit, and
phosphorylation of Thr172 in the activation loop of the a catalytic
subunit by upstream kinases, such as LKB1 and calmodulin-
dependent protein kinase kinase (CaMKK) [18]. AMPK is activated
under ATP-depleting stresses such as glucose deprivation, hypoxia,
and ischemia, and plays a pivotal role in energy homeostasis.
Recent studies indicate that AMPK plays a role in linking metabolic
syndrome and cancer [19,20]. The AMPK signaling network con-
tains a number of tumor suppressor genes, including LKB1, p53, and
TSC2. The tumor suppressor LKB1 has been identiﬁed as an up-
stream activator of AMPK, and other tumor suppressorsdp53 and
TCS2dare direct substrates of AMPK [20]. In addition to causing
cell death, AMPK activation can protect cancer cells against
apoptosis in several cases. For example, AMPK activation di-
minishes apoptosis exposed to anticancer drugs in human gastric
carcinoma [21] and glucose deprivation in pancreas cancer cells
[22]. Thus, AMPK has pleiotropic functions in regulating cell pro-
liferation and apoptosis, and it is possible that AMPK might be a
future target for therapy or prevention of the metabolic syndrome
and some cancers.
In this study, we examined the effect of six ginsenosides on cell
growth inhibition of the human hepatoma cell line HepG2. Among
them, ginsenoside-Rh2 showed the most potent ability to inhibit
the growth of cancer cells. Here, we show that some cancer cells
have varying sensitivities to ginsenoside-Rh2-induced apoptosis,
raising questions concerning the mechanism of inconsistent re-
sponses to ginsenoside-Rh2. We discovered that the degree of
ginsenoside-Rh2-induced AMPK activation correlates with differ-
ences in sensitivity to apoptosis in cancer cell lines. We also
observed that p38 MAPK (mitogen-activated protein kinase) acts as
a survival factor under ginsenoside-Rh2 treatment, but there was
no crosstalk between AMPK and p38 MAPK.
2. Materials and methods
2.1. Cell culture and materials
HepG2, HeLa, DU145, and HCT116 cells were maintained in
RPMI supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics at 37C with 95% air and 5% CO2. RPMI Me-
dium 1640 and FBS were purchased from Life Technologies (Grand
Island, NY, USA). Compound C was a generous gift from Merck
(Darmstadt, Germany). SP600125 and SB203580 were obtained
from TOCRIS (Ellisville, MO, USA). 2,7-Dichloroﬂuorescein (DCFH),
N-acetylcysteine (NAC), PD98059, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and Hoechst 33342 wereobtained from Sigma-Aldrich (St. Louis, MO, USA). The antibodies
that recognize a phosphoactivated form of AMPK-Thr172, and
phosphoactivated and total form ACC (Ser79), extracellular signal-
regulated kinase (ERK)1 and 2 (Thr202/Tyr204), c-Jun NH2-termi-
nal kinase(JNK; Thr183/Tyr185), and p38 (Thr180/Tyr182) were
from Cell Signaling Technology (Boston, MA, USA). The antibody for
poly(ADP-ribose) polymerase (PARP) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The AMPKa antibody was
purchased from Upstate Biotechnology (Lake Placid, NY, USA).
Ginsenoside-Rc, Rd, Re, Rg3, Rh1, and Rh2 were isolated using a
previously described method [23].
2.2. Protein extract and Western blot analysis
HepG2, HeLa, DU154, and HCT116 cells were grown in six-well
plates and werewashed with cold phosphate-buffered saline (PBS),
and lysis buffer (50 mM TriseHCl at pH 7.4, 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 mM sodium orthovanadate, 1 mM NaF,
1 mg/mL leupeptin, 1 mg/mL aprotinin, and 1 mg/mL pepstatin;
Sigma-Aldrich) was then added to the cells. The plate was gently
shaken on ice for 3 min, and the buffer was collected for Western
blot analysis. Protein samples were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and were transferred to
nitrocellulose membranes. The membranes were blocked, incu-
bated with primary antibody, washed, and incubated with the
secondary HRP-conjugated antibody. The bands were visualized
with ECL (Enhanced Chemiluminescence) (Amersham Biosciences,
Piscataway, NJ, USA).
2.3. MTT assay
Cells seeded on 96-well microplates at 4,000 per well were
incubated with the test compounds for the indicated times. After
treatment, media were removed and cells were then incubated
with 100 mLMTT solution (2mg/mLMTT in PBS) for 4 h. Absorbance
was determined using an autoreader.
2.4. Chromatin staining with Hoechst 33342
Apoptosis was observed by chromatin staining with Hoechst
33342. Cells were incubated with each stimulus. After incubation
the supernatant was discarded, and the cells were ﬁxed with 3.5%
formaldehyde (Sigma-Aldrich) in PBS for 30 min at room temper-
ature, washed four times with PBS, and exposed to Hoechst 33342
at 10 mM for 30 min at room temperature. Cell preparations were
examined under UV illumination with a ﬂuorescence microscope
(Olympus Optical Co., Tokyo, Japan).
2.5. Measurement of reactive oxygen species
Cells were incubated with 10 mM of DCFH diacetate (DCFH-DA)
for 30 min, harvested by trypsinization, collected by centrifugation,
and resuspended in PBS containing 2 mg/mL propidium iodide
(Sigma-Aldrich). After sorting out the viable cells, ﬂuorescence in-
tensity was measured by ﬂow cytometry (Becton-Dickinson, San
Jose, CA, USA) using excitation and emission wavelengths of
488 nm and 525 nm, respectively.
3. Results
3.1. Effect of ginsenoside-Rh2 on cell proliferation of cancer cells
Several recent reports have implicated the effect of ginsenoside-
Rh2 on cancer cell death [24e26]. We examined the effect of
Fig. 3. Ginsenoside-Rh2 activates AMP-activated protein kinase (AMPK) in HepG2,
DU145, HCT116 cells, but not HeLa cells. HepG2, HeLa, DU145, and HCT116 cells were
treated with 25 mM or 50 mM ginsenoside-Rh2 for 4 h. Under these conditions, the
phosphorylated and total form of AMPK was examined via Western blot assay using
J Ginseng Res 2014;38:16e2118various ginsenosides, such as ginsenoside-Rc, Rd, Re, Rg3, Rh1, and
Rh2, on cellular proliferation and growth using the MTT assay.
HepG2 cells were exposed to increasing concentrations (25e
50 mM) of each ginsenoside for 48 h. Among them, treatment of
ginsenoside-Rh2 (25 mM or 50 mM) for 48 h induced a signiﬁcant
growth inhibition in HepG2 human hepatocellular carcinoma
(Fig. 2A). Also, a more signiﬁcant dose-dependent growth inhibi-
tory effect is observed in cervical carcinoma (HeLa) than in any
other cancer cell lines testeddhepatoma (HepG2), prostate carci-
noma (DU145), and colon cancer (HCT116) cell linesdfor 24 h
treatment (Fig. 2B).speciﬁc antibodies.3.2. Ginsenoside-Rh2 enhances AMPK activity and AMPK plays an
antiapoptotic role in ginsenoside-Rh2 apoptosis
As shown in Fig. 2, some cancer cells have differential sensitivity
to ginsenoside-Rh2-induced apoptosis, raising questions regarding
the speciﬁc mechanisms responsible for this sensitivity. Because
several recent reports have implicated the role of AMPK in pre-
venting apoptosis in various cancer cell type [21,22], we examined
the ability of ginsenoside-Rh2 to enhance AMPK activity in a variety
of cancer cells. To measure AMPK activity, we used phospho-spe-
ciﬁc (Phospho-Thr172) antibody for AMPK. As shown in Fig. 3,
treatment with ginsenoside-Rh2 25 or 50 mM for 4 h signiﬁcantly
induces AMPK activation in HepG2, DU145, and HCT116 cells, but
not in HeLa cells. Because HeLa cells do not induce AMPK activation
and exhibit relatively more sensitivity to ginsenoside-Rh2-induced
apoptosis (Fig. 2B), we examined the correlation with AMPK ac-
tivity and cell death. The results show that pharmacological inhi-
bition of AMPK, in the presence of the AMPK inhibitor (compound
C), reduces cell viability in HepG2 cells. The combined treatment of
compound C with ginsenoside-Rh2 (25 mM) resulted in lower cell
viability than treatment with ginsenoside-Rh2 alone for the indi-
cated periods. Apoptotic cells were assessed using MTT (Fig. 4A)
and Hoechst 33342 staining (Fig. 4B). Additionally, it was shown
throughWestern blot analysis that PARP cleavage was substantially
increased in compound C-treated cells (Fig. 4C). Although ginse-
noside-Rh2 treatment induces AMPK activation in HepG2 cells, it
does not affect AMPK activity in HeLa cells, and thereby treatment
with the AMPK inhibitor does not affect the degree of PARP
cleavage (Fig. 4D). These results indicated that the AMPK signaling
pathway is important in blocking ginsenoside-Rh2-induced
apoptosis, and that AMPK plays a critical role as an antiapoptotic
molecule.Fig. 2. Ginsenoside-Rh2 induces apoptosis in various cancer cells. (A) HepG2 cells were trea
(a human hepatocellular carcinoma), DU145 (a human prostate carcinoma), HCT116 (a huma
the indicated concentration of ginsenoside-Rh2 for 24 h. Cell growth inhibition was analy
described in Materials and methods.3.3. AMPK activation is mediated by ginsenoside-Rh2-induced
reactive oxygen species generation
Recently, studies reported that AMPK is activated by reactive
oxygen species (ROS) generation in various cell lines [27,28]. To
investigate whether ginsenoside-Rh2 induces ROS production, and
thereby affects AMPK activity, HepG2 cells were treatedwith 25 mM
ginsenoside-Rh2 for 8 h, and ROS was then measured using ﬂow
cytometric analysis of DCFH-DA-stained cells. As shown in Fig. 5A,
ginsenoside-Rh2 induces an increase in ROS level, and treatment of
10 mM NAC blocks ginsenoside-Rh2-induced ROS generation. We
next examined the effect of ROS production on AMPK activity after
treatment of 25 mM ginsenoside-Rh2 both with and without 10 mM
NAC for 8 h. The result shows that NAC treatment completely blocks
ginsenoside-Rh2-induced AMPK activation (Fig. 5B) in HepG2 cells.
These results indicate that AMPK activation is mediated by ginse-
noside-Rh2-induced ROS generation.3.4. Ginsenoside-Rh2 activates ERK, JNK, and p38 MAPK
MAPKs are known to correlate with the pharmacological effects
of ginsenosides. Ginsenoside-Rh2-induced late-phase activation of
JNK is associated with the induction of apoptosis via the proteolytic
dissociation of p21WAF/CIP1 from JNK1-containing complexes [29].
ERK activation inhibits ginseng metabolite, IH-901-induced
apoptosis and cell cycle arrest, via COX-2 induction [30]. The anti-
proliferative effect of ginsenoside-Rg1 is involved in the inhibition
of ERK in cultured human arterial vascular smooth muscle cell [31].
Thus, we next examined whether the MAPK pathway is associated
with ginsenoside-Rh2-induced apoptosis and the antiapoptotic
effects of AMPK in HepG2 cells. As shown in Fig. 6A, ginsenoside-ted with 25 mM or 50 mM ginsenoside-Rc, Rd, Re, Rg3, Rh1, and Rh2 for 48 h. (B) HepG2
n colon carcinoma), and HeLa (a human cervix adenocarcinoma) cells were treated with
zed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as
Fig. 4. Inhibition of AMP-activated protein kinase (AMPK) enhances ginsenoside-Rh2-induced apoptosis in HepG2 cells but not HeLa cells. (A) HepG2 cells were exposed to 25 mM
ginsenoside-Rh2 for the indicated period with or without 20 mM compound C and then analyzed for apoptosis via MTT assay. (B) Cells were cotreated with 20 mM compound C and
25 mM ginsenoside-Rh2 for 8 h. The apoptotic cell death was examined with Hoechst staining by ﬂuorescence microscope. HepG2 (C) and HeLa (D) cells were exposed to 25 mM
ginsenoside-Rh2 for the indicated period with or without 20 mM compound C. Total cell extracts were prepared under the identical conditions and subjected to Western blot assay
using antibody against the phosphorylated form of acetyl-CoA carboxylase (P-ACC), the phosphorylated form of AMPK (P-AMPK), AMPKa and PARP speciﬁc antibodies. MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly(ADP-ribose) polymerase.
M.-J. Kim et al / AMPK in G-Rh2-induced apoptosis 19Rh2 induces the activation of three MAPKs in a time-dependent
manner. To determine whether the activity of the three MAPKs was
involved in ginsenoside-Rh2-induced apoptosis, HepG2 cells were
pretreated with 20 mM PD98059, SB203580, and SP600152, a se-
lective inhibitor of ERK, p38 MAPK, and JNK, respectively. Cotreat-
ment with ginsenoside-Rh2 and SB203580 (p38 MAPK inhibitor)
causes cell death to increase from 20% to 50%, compared with
ginsenoside-Rh2 treatment alone, suggesting that the inhibition of
p38 MAPK can enhance ginsenoside-Rh2-induced apoptosis in
HepG2 cells. However, there was no observed effect of ERK or JNK
inhibition on cell death.
To examinewhether there was a correlation between AMPK and
p38MAPK activity, we investigated AMPK and p38MAPK activation
following each kinase inhibition by compound C or SB203580. As
shown in Fig. 6C, inhibition of AMPK did not affect p38 MAPK ac-
tivity, and inhibition of p38 MAPK did not affect AMPK activity,
either. Therefore, it is likely that AMPK and p38 MAPK transmit its
signal in an independent manner.
4. Discussion
Ginseng, the root of P. ginseng, is a medicinal herb that has been
reported to have various biological effects, including anticarcino-
genic activities. Ginseng extracts induce apoptosis, and decrease
telomerase activity and cyclooxygenase-2 (COX-2) expression in
human leukemia cells [32]. In addition, ginseng extracts suppress
colon carcinogenesis induced by 1,2-dimethylhydrazine with inhi-
bition of cell proliferation [33]. Among them, ginsenoside-Rh2 is
recognized as a major active anticancer saponin [34]. Ginsenoside-
Rg3 is known to metabolize to ginsenoside-Rh2 by humanintestinal bacteria [35]. In this regard, the anticancer activity of two
compounds has been compared in many reports. In the case of
Hep3B cells, these two compounds induce apoptosis through a
mitochondrial pathway [36]. However, several reports demon-
strated that ginsenoside-Rh2 showed a more potent anticancer
activity than ginsenoside-Rg3 [37,38]. Ginsenoside-Rh2 treatment
modulates the protein level of p21 and cyclin D, which results in a
marked reduction in proliferation on MCF-7 human breast cancer
cells [16]. Ginsenoside-Rh2 also induces apoptosis through the
activation of p53 and the increase of the proapoptotic regulator,
Bax, in colorectal cancer cells [37]. In addition, Ginsenoside-Rh2
markedly inhibits the viability of breast cancer cells (MCF-7 and
MDA-MB-231) with G1 phase cell cycle arrest, which is caused by
p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent
kinases [10]. Although many studies describing the anticancer ef-
fect of ginsenoside-Rh2 have been conducted, much of its mecha-
nism relating to anticancer activities remains unclear.
AMPK is a pleiotropic kinase that signals for both survival and
apoptosis of cells. It plays a key role as a regulator of cellular energy
homeostasis [39]. The kinase is activated in response to ATP de-
pletions, such as those of glucose starvation, hypoxia, ischemia, and
heat shock. Moreover, a proapoptotic function of AMPK was also
reported, where the connection of AMPK with several tumor sup-
pressors suggests that AMPK is a mediator of apoptosis. The LKB1
tumor suppressor that mutated in PeutzeJeghers syndrome
directly phosphorylates and activates AMPK [40,41]. The TSC2 tu-
mor suppressor is directly phosphorylated by AMPK, and the
AMPK-mediated phosphorylation of TSC2 has an important role in
cell survival [42,43]. The present study focuses on identifying the
mechanism that underlies the anticancer activity of ginsenoside-
Fig. 5. AMP-activated protein kinase (AMPK) is activated by ginsenoside-Rh2-medi-
ated reactive oxygen species (ROS) generation. (A) HepG2 cells were exposed to 25 mM
ginsenoside-Rh2 for 4 h, and then DCFH-DA (10 mM) was added for 30 min. The
changes in ﬂuorescence intensity were measured by ﬂuorescence-activated cell
scanning analysis. (B) After exposure to 25 mM ginsenoside-Rh2 for 4 h in the presence
or absence of 1 mM NAC (N-acetyl-cysteine), the phosphorylated and total level of
AMPK were examined. DCFH-DA, 2,7-Dichloroﬂuorescein-diacetate.
J Ginseng Res 2014;38:16e2120Rh2. In this study, we show that in HepG2 cells treated with gin-
senoside-Rh2, AMPK activity is increased in a time- and dose-
dependent manner (Figs. 3 and 4C). To conﬁrm the role of AMPK in
ginsenoside-Rh2-induced apoptosis, HepG2 cells were treated with
ginsenoside-Rh2, and were then assessed for the degree of
apoptosis according to the degree of variation in AMPK activity. InFig. 6. Ginsenoside-Rh2 activates MAPKs, and both AMPK and p38 protect cells from ginsen
ginsenoside-Rh2 for the indicated period and the phosphorylated and total form of the indic
using speciﬁc antibodies. (B) Cells were pre-treated with each kinase inhibitor (20 mM) comp
and then cells were exposed for 24 h to 25 mM ginsenoside-Rh2 for 24 h. Cell viability was
compound C (AMPK) and SB203580 (p38 MAPK) for 30 min and were then exposed to 25 m
assay using phosphorylated and total form of the indicated protein and PARP speciﬁc antib
MAPK, mitogen-activated protein kinases; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltethis study, we have shown that AMPK activity is caused by ginse-
noside-Rh2-mediated ROS generation (Fig. 5), and that it contrib-
utes to cancer cell growth and survival under treatment with
ginsenoside-Rh2 (Fig. 4). These observations indicate that AMPK
can function as an antiapoptotic molecule.
It is well documented that MAPK pathways modulate gene
expression, mitosis, proliferation, metabolism, and apoptosis. Pre-
vious studies have demonstrated thatMAPK signaling is involved in
ginsenoside-mediated anticarcinogenesis. Ginsenoside Rg3 and
Rh2 inhibit the proliferation of prostate cancer cells by modulating
MAPK [17]. Ginsenoside Rb1 inhibits histamine release and IL-4
production induced by substance P, a neurotransmitter, via the ERK
pathway [44]. A ginseng saponin metabolite, compound K, sup-
presses phorbol ester-induced matrix metalloproteinase-9
expression through the inhibition of MAPK signaling in human
astroglioma cells [45]. Our results show that p38 MAPK activity is
involved in ginsenoside-Rh2-mediated apoptosis (Fig. 6B,C). The
induction of ginsenoside-Rh2-mediated apoptosis by p38 MAPK
inhibitor SB203580 suggests that p38 MAPK signaling is important
in protecting cancer cell against apoptosis. However, the molecular
mechanism involved in the antiapoptotic role of p38MAPK remains
unclear and needs to be studied further.
Recently, several reports have also linked AMPK activity to p38
MAPK. AMPK activator AICAR increases glucose uptake by acti-
vating the p38 MAPK pathway, but the p38 MAPK inhibitor did not
affect AMPK activation by AICAR in skeletal muscle [46]. The reti-
noic acid-mediated activation of p38 MAPK was inhibited by
treatment with the AMPK inhibitor, compound C [47]. However, a
further study suggests that AMPK activation leads to p38 MAPK
inhibition. p38 MAPK is induced by the addition of cAMP to serum-
starved H4IIE cells, and it is inhibited with AICAR treatment [48].
Even though several reports show that AMPK regulates p38 MAPK
activity, the underlying mechanism of this interaction is not clearly
understood. In this regard, we also examined if there is any cross-
talk between AMPK and p38 MAPK (Fig. 6C), but there was no
signaling crosstalk between these two kinases. Our present obser-
vations provide the rationale for a combination of AMPK and p38
MAPK inhibitors in the treatment of cancer, and future studies
focusing on the molecular mechanism of AMPK and p38 MAPK in
ginsenoside-Rh2-induced apoptosis would greatly extend our un-
derstanding of the chemotherapeutic potency of ginsenoside-Rh2
in human cancer.oside-Rh2-induced apoptosis in HepG2 cells. (A) HepG2 cells were treated with 25 mM
ated protein including p38 MAPK, c-Jun NH2-terminal kinase (JNK), ERK, was examined
ound C (AMPK), SB203580 (p38 MAPK), SP600125 (JNK), and PD98059 (ERK) for 30 min
measured by MTT assay. (C) Cells were pretreated with each kinase inhibitor (20 mM)
M ginsenoside-Rh2 for 4 h, and then total cell extracts were subjected to Western blot
odies. AMPK, AMP-activated protein kinase; ERK, extracellular signal-regulated kinase;
trazolium bromide; PARP, poly(ADP-ribose) polymerase.
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